NCT07712523 QY-201 Nonsegmental vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07712523 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 21 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07712523 is a hot trial to watch
Nonsegmental vitiligo is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07712523 is notable because it evaluates QY-201 in a Phase 2 design sponsored by E-Nitiate Biopharmaceuticals Hangzhou Co. Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07712523 |
| Official title | A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo |
| Phase / status | Phase 2 / Recruiting |
| Intervention | QY-201 |
| Sponsor | E-Nitiate Biopharmaceuticals Hangzhou Co. Ltd. |
| Geography | China |
| Enrollment | 200 |
| Primary endpoint | Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24 of treatment. |
| Endpoint time frame | Week 24 of protocol-specified treatment |
| Primary completion / readout proxy | 2026-12-31 |
Protocol design and endpoint interpretation
To evaluate the efficacy of QY201 Tablets in adult subjects with non-segmental vitiligo, and to provide evidence for dose selection in the confirmatory Phase III clinical trial.
Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment. Planned enrollment of 200 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24 of treatment. (Week 24 of protocol-specified treatment) — To evaluate the difference in the percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) between the treatment group and the placebo group in subjects with non-segmental vitiligo after completion of 24 weeks of protocol-specified treatment. Subjects who discontinue treatment prematurely due to poor efficacy, or receive prohibited concomitant medications specified in the protocol that interfere
Readout outlook and evidence gap
The current protocol points to 2026-12-31 as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Trial-sourced asset: QY-201. The Drug & Asset MCP enrichment step is designed to add normalized targets, modality and global development status when an exact asset match is available.
Trial-sourced sponsor: E-Nitiate Biopharmaceuticals Hangzhou Co. Ltd.. Company & Deal Intelligence MCP is the companion workflow for resolving organization identity, corporate profile and partnering context.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07712523 provides a focused lens on Nonsegmental vitiligo development. Its value will be determined by whether QY-201 can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
